CheckMate 9LA: First-line nivolumab + ipilimumab + 2 cycles chemotherapy vs 4 cycles chemo in aN... скачать в хорошем качестве

CheckMate 9LA: First-line nivolumab + ipilimumab + 2 cycles chemotherapy vs 4 cycles chemo in aN...

Dr Luis Paz-Ares speaks to ecancer about the CheckMate 9LA study. It investigates the first-line nivolumab + ipilimumab + 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC. Initially, he explains the rationale of his study. In this study, the efficacy of nivolumab + ipilimumab and chemotherapy was evaluated by tissue and blood TMB (tTMB/bTMB). He then talks about the methodology of his study. Dr Paz-Ares further discusses the results of his study. He says that higher TMB appeared to be associated with improved PFS and ORR benefits of NIVO + IPI + chemo over chemo. OS benefit was generally similar between high and low TMB. In the end, he discusses the future impact of this study on the treatment of NSCLC. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php